Jennifer Patnaik
Concepts (430)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 31 | 2026 | 486 | 5.060 |
Why?
| | Cataract | 18 | 2024 | 238 | 3.840 |
Why?
| | Macular Degeneration | 16 | 2025 | 191 | 3.740 |
Why?
| | Geographic Atrophy | 12 | 2025 | 97 | 3.550 |
Why?
| | Phacoemulsification | 14 | 2025 | 122 | 2.560 |
Why?
| | Wet Macular Degeneration | 7 | 2025 | 57 | 2.130 |
Why?
| | Registries | 10 | 2025 | 2253 | 2.120 |
Why?
| | Diabetic Retinopathy | 13 | 2024 | 207 | 2.070 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 49 | 1.840 |
Why?
| | Tomography, Optical Coherence | 11 | 2025 | 264 | 1.780 |
Why?
| | Fluorescein Angiography | 10 | 2026 | 184 | 1.720 |
Why?
| | Intraocular Pressure | 12 | 2026 | 327 | 1.610 |
Why?
| | Cataract Extraction | 11 | 2026 | 119 | 1.600 |
Why?
| | Ophthalmology | 6 | 2025 | 116 | 1.440 |
Why?
| | Optometrists | 3 | 2026 | 12 | 1.180 |
Why?
| | Glaucoma | 8 | 2025 | 250 | 1.150 |
Why?
| | Optometry | 2 | 2025 | 9 | 1.120 |
Why?
| | Retinopathy of Prematurity | 4 | 2026 | 179 | 1.110 |
Why?
| | Keratomileusis, Laser In Situ | 3 | 2024 | 20 | 1.090 |
Why?
| | Follow-Up Studies | 26 | 2026 | 5350 | 1.070 |
Why?
| | Retinal Detachment | 6 | 2023 | 71 | 0.970 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 21 | 0.940 |
Why?
| | Retrospective Studies | 57 | 2026 | 16937 | 0.930 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.930 |
Why?
| | Acanthamoeba Keratitis | 1 | 2025 | 4 | 0.930 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 7 | 0.920 |
Why?
| | Myopia | 7 | 2024 | 59 | 0.910 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.910 |
Why?
| | Aged, 80 and over | 29 | 2025 | 8185 | 0.900 |
Why?
| | Aged | 51 | 2026 | 25822 | 0.820 |
Why?
| | Burnout, Professional | 3 | 2025 | 481 | 0.800 |
Why?
| | Humans | 124 | 2026 | 144859 | 0.790 |
Why?
| | Refraction, Ocular | 6 | 2024 | 47 | 0.780 |
Why?
| | Capsule Opacification | 2 | 2021 | 22 | 0.730 |
Why?
| | Intraoperative Complications | 6 | 2024 | 155 | 0.720 |
Why?
| | Presbyopia | 1 | 2022 | 15 | 0.710 |
Why?
| | Female | 78 | 2026 | 78217 | 0.700 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.700 |
Why?
| | Eye Diseases | 2 | 2020 | 94 | 0.700 |
Why?
| | Uveitis | 4 | 2025 | 147 | 0.700 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 8 | 0.700 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.690 |
Why?
| | Surveys and Questionnaires | 14 | 2026 | 6052 | 0.680 |
Why?
| | Trabeculectomy | 5 | 2025 | 75 | 0.680 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 23 | 0.680 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.670 |
Why?
| | Male | 71 | 2026 | 72189 | 0.640 |
Why?
| | Automobile Driving | 2 | 2022 | 155 | 0.640 |
Why?
| | Colorado | 22 | 2026 | 4606 | 0.630 |
Why?
| | Glaucoma, Open-Angle | 4 | 2023 | 104 | 0.620 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 28 | 0.610 |
Why?
| | Laser Therapy | 1 | 2021 | 136 | 0.600 |
Why?
| | Dementia | 1 | 2023 | 299 | 0.600 |
Why?
| | Middle Aged | 40 | 2026 | 35939 | 0.580 |
Why?
| | Vitrectomy | 6 | 2025 | 72 | 0.580 |
Why?
| | Postoperative Complications | 7 | 2026 | 2934 | 0.570 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 142 | 0.570 |
Why?
| | Lens, Crystalline | 1 | 2020 | 136 | 0.560 |
Why?
| | Lasers, Excimer | 3 | 2024 | 30 | 0.540 |
Why?
| | Metformin | 1 | 2021 | 332 | 0.530 |
Why?
| | Angiogenesis Inhibitors | 3 | 2026 | 236 | 0.530 |
Why?
| | Strabismus | 3 | 2023 | 70 | 0.520 |
Why?
| | Complement Activation | 5 | 2025 | 412 | 0.510 |
Why?
| | West Nile Fever | 3 | 2011 | 57 | 0.510 |
Why?
| | Emergency Medicine | 1 | 2019 | 259 | 0.490 |
Why?
| | Laser Coagulation | 3 | 2026 | 76 | 0.490 |
Why?
| | Internal Medicine | 1 | 2019 | 278 | 0.490 |
Why?
| | Cross-Sectional Studies | 13 | 2026 | 5809 | 0.480 |
Why?
| | Refractive Errors | 3 | 2025 | 36 | 0.480 |
Why?
| | Complement System Proteins | 4 | 2025 | 317 | 0.470 |
Why?
| | Choroid | 3 | 2025 | 79 | 0.460 |
Why?
| | Prevalence | 7 | 2025 | 2830 | 0.460 |
Why?
| | Family Practice | 1 | 2019 | 416 | 0.460 |
Why?
| | Self Report | 2 | 2022 | 871 | 0.450 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2026 | 561 | 0.420 |
Why?
| | United States | 19 | 2026 | 15723 | 0.420 |
Why?
| | Breast Neoplasms | 3 | 2011 | 2517 | 0.410 |
Why?
| | Lens Implantation, Intraocular | 5 | 2022 | 80 | 0.410 |
Why?
| | Cornea | 3 | 2025 | 155 | 0.410 |
Why?
| | Biomarkers | 9 | 2025 | 4279 | 0.400 |
Why?
| | Multimodal Imaging | 2 | 2025 | 122 | 0.400 |
Why?
| | Corneal Transplantation | 2 | 2025 | 17 | 0.390 |
Why?
| | Internet | 4 | 2023 | 702 | 0.390 |
Why?
| | Glucocorticoids | 4 | 2026 | 540 | 0.390 |
Why?
| | Commerce | 2 | 2013 | 78 | 0.390 |
Why?
| | Vitreous Body | 4 | 2022 | 116 | 0.390 |
Why?
| | Diabetes Mellitus | 5 | 2024 | 1089 | 0.380 |
Why?
| | Fluocinolone Acetonide | 2 | 2023 | 15 | 0.380 |
Why?
| | Smoking Prevention | 1 | 2013 | 170 | 0.370 |
Why?
| | Tobacco Products | 1 | 2013 | 89 | 0.360 |
Why?
| | Risk Factors | 14 | 2025 | 10672 | 0.360 |
Why?
| | Ophthalmologic Surgical Procedures | 2 | 2025 | 90 | 0.360 |
Why?
| | Macula Lutea | 2 | 2023 | 19 | 0.360 |
Why?
| | Fundus Oculi | 3 | 2025 | 88 | 0.340 |
Why?
| | Disease Notification | 2 | 2011 | 16 | 0.340 |
Why?
| | Retinal Diseases | 2 | 2023 | 98 | 0.340 |
Why?
| | Lens Capsule, Crystalline | 2 | 2021 | 13 | 0.330 |
Why?
| | Complement Factor B | 2 | 2022 | 106 | 0.310 |
Why?
| | Artificial Intelligence | 2 | 2024 | 370 | 0.310 |
Why?
| | Treatment Outcome | 12 | 2026 | 11581 | 0.300 |
Why?
| | Comorbidity | 2 | 2011 | 1640 | 0.300 |
Why?
| | Tonometry, Ocular | 3 | 2025 | 103 | 0.300 |
Why?
| | Eye Injuries | 2 | 2021 | 53 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2599 | 0.280 |
Why?
| | Tertiary Care Centers | 2 | 2026 | 186 | 0.280 |
Why?
| | Infant | 13 | 2026 | 9987 | 0.270 |
Why?
| | Bangladesh | 3 | 2022 | 61 | 0.260 |
Why?
| | Hepatitis A | 2 | 2011 | 29 | 0.260 |
Why?
| | West Nile virus | 1 | 2007 | 41 | 0.260 |
Why?
| | Healthcare Disparities | 2 | 2025 | 712 | 0.260 |
Why?
| | Gestational Age | 4 | 2026 | 977 | 0.250 |
Why?
| | Adult | 24 | 2026 | 40438 | 0.250 |
Why?
| | Time Factors | 7 | 2025 | 7107 | 0.250 |
Why?
| | Local Government | 1 | 2006 | 27 | 0.250 |
Why?
| | Health Promotion | 1 | 2013 | 782 | 0.250 |
Why?
| | Pars Planitis | 1 | 2026 | 6 | 0.240 |
Why?
| | Restaurants | 1 | 2006 | 22 | 0.240 |
Why?
| | Prospective Studies | 7 | 2025 | 7947 | 0.240 |
Why?
| | Keratoconjunctivitis | 1 | 2026 | 11 | 0.240 |
Why?
| | Vision Disorders | 3 | 2022 | 177 | 0.240 |
Why?
| | Chronic Disease | 2 | 2011 | 1833 | 0.240 |
Why?
| | Blepharitis | 1 | 2026 | 9 | 0.240 |
Why?
| | Scleritis | 2 | 2025 | 28 | 0.230 |
Why?
| | Public Health Administration | 1 | 2006 | 73 | 0.230 |
Why?
| | Retinal Degeneration | 1 | 2026 | 40 | 0.230 |
Why?
| | Mass Screening | 2 | 2024 | 1331 | 0.230 |
Why?
| | Blindness | 1 | 2026 | 51 | 0.230 |
Why?
| | Eye Proteins | 1 | 2026 | 92 | 0.230 |
Why?
| | Visual Fields | 1 | 2026 | 117 | 0.230 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 42 | 0.230 |
Why?
| | Dry Eye Syndromes | 1 | 2026 | 55 | 0.230 |
Why?
| | Ciliary Body | 1 | 2025 | 40 | 0.220 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.220 |
Why?
| | Keratoconus | 1 | 2025 | 23 | 0.220 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.220 |
Why?
| | Withholding Treatment | 1 | 2025 | 79 | 0.220 |
Why?
| | Occupational Stress | 1 | 2025 | 46 | 0.210 |
Why?
| | Surgery, Plastic | 1 | 2025 | 53 | 0.210 |
Why?
| | Birth Weight | 3 | 2022 | 524 | 0.210 |
Why?
| | Education, Distance | 1 | 2025 | 61 | 0.210 |
Why?
| | Quality of Life | 5 | 2023 | 3165 | 0.210 |
Why?
| | Retinoblastoma | 1 | 2024 | 50 | 0.210 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.210 |
Why?
| | Child | 14 | 2026 | 22620 | 0.210 |
Why?
| | Young Adult | 7 | 2026 | 14033 | 0.200 |
Why?
| | Optics and Photonics | 2 | 2021 | 41 | 0.200 |
Why?
| | Disease Progression | 4 | 2025 | 2881 | 0.200 |
Why?
| | Adolescent | 12 | 2026 | 22396 | 0.200 |
Why?
| | Telemedicine | 2 | 2024 | 952 | 0.200 |
Why?
| | Macular Edema | 1 | 2023 | 48 | 0.190 |
Why?
| | Postoperative Period | 5 | 2025 | 354 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2024 | 1086 | 0.190 |
Why?
| | Insulins | 1 | 2023 | 39 | 0.190 |
Why?
| | Job Satisfaction | 1 | 2025 | 238 | 0.190 |
Why?
| | Eye Burns | 1 | 2022 | 14 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2026 | 353 | 0.190 |
Why?
| | Homosexuality, Male | 2 | 2020 | 215 | 0.190 |
Why?
| | Vision, Low | 1 | 2022 | 17 | 0.190 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 80 | 0.190 |
Why?
| | Cohort Studies | 6 | 2022 | 5898 | 0.190 |
Why?
| | Endoscopy | 1 | 2025 | 330 | 0.190 |
Why?
| | Eyelid Diseases | 1 | 2022 | 25 | 0.180 |
Why?
| | Compartment Syndromes | 1 | 2022 | 36 | 0.180 |
Why?
| | Odds Ratio | 4 | 2019 | 1058 | 0.180 |
Why?
| | Eyeglasses | 1 | 2022 | 24 | 0.180 |
Why?
| | Corneal Ulcer | 1 | 2022 | 20 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2865 | 0.180 |
Why?
| | Retinal Perforations | 1 | 2022 | 18 | 0.180 |
Why?
| | Clothing | 1 | 2022 | 22 | 0.180 |
Why?
| | Infant, Newborn | 6 | 2026 | 6406 | 0.170 |
Why?
| | Ocular Hypertension | 1 | 2022 | 70 | 0.170 |
Why?
| | Patient Satisfaction | 2 | 2024 | 712 | 0.170 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.170 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.170 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 7 | 0.170 |
Why?
| | Neonatal Screening | 1 | 2022 | 177 | 0.170 |
Why?
| | Eye Banks | 1 | 2020 | 7 | 0.170 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 60 | 0.160 |
Why?
| | Glaucoma Drainage Implants | 1 | 2021 | 46 | 0.160 |
Why?
| | Child, Preschool | 10 | 2026 | 11740 | 0.160 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.160 |
Why?
| | Perception | 2 | 2021 | 381 | 0.160 |
Why?
| | Glycation End Products, Advanced | 1 | 2021 | 87 | 0.160 |
Why?
| | Accidents, Traffic | 1 | 2022 | 190 | 0.160 |
Why?
| | SEER Program | 2 | 2011 | 225 | 0.160 |
Why?
| | Health Services Accessibility | 2 | 2026 | 1092 | 0.160 |
Why?
| | Scleral Buckling | 1 | 2019 | 15 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 149 | 0.160 |
Why?
| | Retinal Hemorrhage | 1 | 2019 | 21 | 0.150 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2019 | 14 | 0.150 |
Why?
| | Language | 1 | 2023 | 323 | 0.150 |
Why?
| | Hepatitis C | 1 | 2022 | 252 | 0.150 |
Why?
| | Legislation, Drug | 1 | 2020 | 77 | 0.150 |
Why?
| | Protective Factors | 1 | 2019 | 102 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2023 | 318 | 0.150 |
Why?
| | Head Injuries, Closed | 1 | 2019 | 50 | 0.150 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 85 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 74 | 0.150 |
Why?
| | Risk Assessment | 3 | 2019 | 3580 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 134 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 41 | 0.150 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.150 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2109 | 0.150 |
Why?
| | Accreditation | 1 | 2019 | 98 | 0.150 |
Why?
| | Refugees | 1 | 2020 | 82 | 0.140 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 57 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 123 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 119 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2022 | 3628 | 0.140 |
Why?
| | Down Syndrome | 1 | 2025 | 535 | 0.140 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 23 | 0.140 |
Why?
| | Infant, Premature | 1 | 2022 | 612 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 282 | 0.140 |
Why?
| | Curriculum | 1 | 2025 | 1058 | 0.140 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 80 | 0.130 |
Why?
| | Sexually Transmitted Diseases | 3 | 2004 | 168 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 230 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2026 | 1332 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2020 | 259 | 0.120 |
Why?
| | Marijuana Use | 1 | 2020 | 218 | 0.120 |
Why?
| | Clinical Competence | 2 | 2025 | 1238 | 0.120 |
Why?
| | Logistic Models | 2 | 2019 | 2098 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 639 | 0.110 |
Why?
| | Recovery of Function | 1 | 2019 | 702 | 0.110 |
Why?
| | Population Surveillance | 2 | 2011 | 491 | 0.110 |
Why?
| | Aging | 1 | 2026 | 1980 | 0.110 |
Why?
| | Inflammation | 3 | 2023 | 2911 | 0.110 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 1307 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 553 | 0.100 |
Why?
| | Disease Outbreaks | 2 | 2008 | 423 | 0.100 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 80 | 0.100 |
Why?
| | Condoms | 2 | 2004 | 101 | 0.100 |
Why?
| | Intravitreal Injections | 2 | 2026 | 71 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 936 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1128 | 0.090 |
Why?
| | Sexual Behavior | 4 | 2004 | 493 | 0.090 |
Why?
| | Melanoma | 1 | 2019 | 813 | 0.090 |
Why?
| | Medicare | 2 | 2024 | 825 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2019 | 863 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 16 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1398 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2024 | 256 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2011 | 176 | 0.080 |
Why?
| | Shellfish Poisoning | 1 | 2009 | 1 | 0.080 |
Why?
| | Vibrio Infections | 1 | 2009 | 2 | 0.080 |
Why?
| | Primary Prevention | 1 | 2011 | 197 | 0.080 |
Why?
| | Shellfish | 1 | 2009 | 6 | 0.080 |
Why?
| | Food Industry | 1 | 2009 | 8 | 0.080 |
Why?
| | Food Microbiology | 1 | 2009 | 73 | 0.070 |
Why?
| | Sex Factors | 2 | 2025 | 2090 | 0.070 |
Why?
| | Cause of Death | 1 | 2011 | 461 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 960 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 364 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1261 | 0.070 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 22 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 542 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2224 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 2 | 2022 | 483 | 0.070 |
Why?
| | Disease Reservoirs | 1 | 2007 | 25 | 0.070 |
Why?
| | Maternal-Child Health Centers | 1 | 2007 | 8 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 33 | 0.070 |
Why?
| | Sentinel Surveillance | 1 | 2007 | 46 | 0.070 |
Why?
| | Gastroenteritis | 1 | 2008 | 62 | 0.070 |
Why?
| | Health Services Administration | 1 | 2007 | 8 | 0.070 |
Why?
| | Relief Work | 1 | 2007 | 18 | 0.060 |
Why?
| | Chickens | 1 | 2007 | 192 | 0.060 |
Why?
| | Telephone | 1 | 2008 | 177 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 858 | 0.060 |
Why?
| | Geography | 1 | 2007 | 202 | 0.060 |
Why?
| | Birds | 1 | 2007 | 92 | 0.060 |
Why?
| | Horses | 1 | 2007 | 204 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2008 | 536 | 0.060 |
Why?
| | Ophthalmologists | 1 | 2026 | 17 | 0.060 |
Why?
| | Ethiopia | 1 | 2026 | 43 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3854 | 0.060 |
Why?
| | Visual Field Tests | 1 | 2026 | 34 | 0.060 |
Why?
| | Disasters | 1 | 2007 | 99 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1557 | 0.060 |
Why?
| | Environment | 1 | 2007 | 307 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2006 | 163 | 0.060 |
Why?
| | Immunization Programs | 1 | 2007 | 193 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2103 | 0.060 |
Why?
| | Bevacizumab | 1 | 2026 | 168 | 0.060 |
Why?
| | Corneal Topography | 1 | 2025 | 25 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1474 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 14 | 0.060 |
Why?
| | Azathioprine | 1 | 2025 | 48 | 0.060 |
Why?
| | Adalimumab | 1 | 2025 | 54 | 0.060 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.060 |
Why?
| | Tomography | 1 | 2025 | 45 | 0.060 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.050 |
Why?
| | Benchmarking | 1 | 2026 | 185 | 0.050 |
Why?
| | Ontario | 1 | 2024 | 94 | 0.050 |
Why?
| | Infliximab | 1 | 2025 | 108 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 120 | 0.050 |
Why?
| | Conjunctivitis | 1 | 2024 | 31 | 0.050 |
Why?
| | Retinal Neoplasms | 1 | 2024 | 42 | 0.050 |
Why?
| | Rwanda | 1 | 2024 | 35 | 0.050 |
Why?
| | Capacity Building | 1 | 2024 | 59 | 0.050 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 79 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 403 | 0.050 |
Why?
| | Patient Discharge | 1 | 2011 | 949 | 0.050 |
Why?
| | Attitude to Health | 1 | 2007 | 436 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 240 | 0.050 |
Why?
| | Vision Tests | 1 | 2023 | 22 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 1080 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 128 | 0.050 |
Why?
| | Health Surveys | 2 | 2021 | 512 | 0.050 |
Why?
| | Postoperative Care | 1 | 2025 | 283 | 0.050 |
Why?
| | Tobacco Use Disorder | 1 | 2005 | 223 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 213 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2011 | 1177 | 0.050 |
Why?
| | Gonorrhea | 1 | 2003 | 65 | 0.050 |
Why?
| | Mentors | 1 | 2024 | 218 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 38 | 0.050 |
Why?
| | Orbit | 1 | 2022 | 66 | 0.050 |
Why?
| | Global Health | 1 | 2025 | 395 | 0.050 |
Why?
| | Hospitals, Pediatric | 1 | 2026 | 554 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3199 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 147 | 0.040 |
Why?
| | Drug Implants | 1 | 2022 | 83 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2023 | 530 | 0.040 |
Why?
| | Nicotine | 1 | 2005 | 331 | 0.040 |
Why?
| | Communication Barriers | 1 | 2023 | 123 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 181 | 0.040 |
Why?
| | Capsulorhexis | 1 | 2021 | 9 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 118 | 0.040 |
Why?
| | Safety-net Providers | 1 | 2023 | 126 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 322 | 0.040 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 180 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 121 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 234 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 68 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2005 | 439 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.040 |
Why?
| | Biometry | 1 | 2021 | 68 | 0.040 |
Why?
| | Myanmar | 1 | 2020 | 6 | 0.040 |
Why?
| | Risk-Taking | 1 | 2003 | 334 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 15 | 0.040 |
Why?
| | Rupture | 1 | 2020 | 86 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 844 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 47 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 501 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 92 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2051 | 0.040 |
Why?
| | HIV | 1 | 2020 | 248 | 0.040 |
Why?
| | Health Education | 1 | 2003 | 360 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 454 | 0.040 |
Why?
| | Canada | 1 | 2020 | 425 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 419 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 40 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2018 | 10 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1873 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 259 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2018 | 38 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 128 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 148 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1054 | 0.030 |
Why?
| | Pseudophakia | 1 | 2018 | 22 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2023 | 517 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2023 | 599 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 576 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2940 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 772 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 235 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2020 | 355 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 621 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2971 | 0.030 |
Why?
| | Ambulatory Care Facilities | 3 | 2004 | 266 | 0.030 |
Why?
| | Stents | 1 | 2021 | 549 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2024 | 949 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 534 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 847 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 790 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 782 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 909 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3411 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1510 | 0.030 |
Why?
| | Program Evaluation | 2 | 2011 | 962 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1114 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1029 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1913 | 0.030 |
Why?
| | Child Abuse | 1 | 2019 | 550 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1196 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2045 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 1003 | 0.020 |
Why?
| | Depression | 1 | 2022 | 1536 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1685 | 0.020 |
Why?
| | Animals | 3 | 2009 | 38331 | 0.020 |
Why?
| | Legionellosis | 1 | 2011 | 2 | 0.020 |
Why?
| | Blood Glucose | 1 | 2021 | 2335 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4253 | 0.020 |
Why?
| | Medical Audit | 1 | 2011 | 76 | 0.020 |
Why?
| | Whooping Cough | 1 | 2011 | 55 | 0.020 |
Why?
| | Haemophilus Infections | 1 | 2011 | 45 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 137 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2011 | 140 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1967 | 0.020 |
Why?
| | Cryptosporidium | 1 | 2008 | 14 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 18 | 0.020 |
Why?
| | Norovirus | 1 | 2008 | 22 | 0.020 |
Why?
| | Aid to Families with Dependent Children | 1 | 2007 | 3 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 375 | 0.020 |
Why?
| | Faculty | 1 | 2008 | 151 | 0.020 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 91 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2007 | 129 | 0.020 |
Why?
| | Family Characteristics | 1 | 2008 | 199 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1987 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2007 | 170 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2009 | 569 | 0.010 |
Why?
| | Maryland | 1 | 2005 | 64 | 0.010 |
Why?
| | Administration, Topical | 1 | 2005 | 153 | 0.010 |
Why?
| | Urban Health Services | 1 | 2004 | 68 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1006 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 91 | 0.010 |
Why?
| | Syphilis | 1 | 2003 | 33 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 844 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 278 | 0.010 |
Why?
| | Risk | 1 | 2004 | 905 | 0.010 |
Why?
| | Mothers | 1 | 2007 | 774 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 493 | 0.010 |
Why?
| | HIV Infections | 1 | 2003 | 3082 | 0.000 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|